The Journal of Laboratory and Clinical Medicine
Volume 145, Issue 6 , Pages 323-327 , June 2005

Effect of influenza vaccine on markers of inflammation and lipid profile

  • Michael Y. Tsai

      Affiliations

    • Laboratory of Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota
    • Corresponding Author InformationReprint requests: Michael Y. Tsai, PhD, 420 Delaware St. SE, Mayo Mail Code 609, Minneapolis, MN 55455-0392
    • ,
  • Naomi Q. Hanson

      Affiliations

    • Laboratory of Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota
    • ,
  • Robert J. Straka

      Affiliations

    • College of Pharmacy, University of Minnesota, Minneapolis, Minnesota
    • ,
  • Tracy R. Hoke

      Affiliations

    • Division of Heart and Vascular Disease/National Heart, Lung, and Blood Institute, Bethesda, Maryland
    • ,
  • Jose M. Ordovas

      Affiliations

    • JM-USDA-HNRCA at Tufts University, Boston, Massachusetts
    • ,
  • James M. Peacock

      Affiliations

    • Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota
    • ,
  • Valerie L. Arends

      Affiliations

    • Laboratory of Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota
    • ,
  • Donna K. Arnett

      Affiliations

    • Department of Epidemiology, University of Alabama, Birmingham, Alabama

Received 12 January 2005 ,Accepted 23 March 2005.

References 

  1. Reinhardt B , Jaspert R , Niedrig M , Kostner C , L’age-Stehr J . Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D (a model of human flavivirus infection) . J Med Virol . 1998;56:159–167
  2. Hacker UT , Jelinek T , Erhardt S , et al.   In vivo synthesis of tumor necrosis factor-alpha in healthy humans after live yellow fever vaccination . J Infect Dis . 1998;177:774–778
  3. van der Beek MT , Visser LG , de Maat MP . Yellow fever vaccination as a model to study the response to stimulation of the inflammation system . Vascul Pharmacol . 2002;39:117–121
  4. Posthouwer D , Voorbij HA , Grobbee DE , Numans ME , van der Bom JG . Influenza and pneumococcal vaccination as a model to assess C-reactive protein response to mild inflammation . Vaccine . 2004;23:362–365
  5. Pearson TA , Mensah GA , Alexander RW , et al.   Markers of inflammation and cardiovascular disease. Application to clinical and public health practice. A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association . Circulation . 2003;107:499–511
  6. Forman BM , Evans RM . Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors [α] and [δ] . Proc Natl Acad Sci U S A . 1997;94:4312–4317
  7. Staels B , Dallongeville J , Auwerx J , Schoonjans K , Leitersdorf E , Fruchart JC . Mechanism of action of fibrates on lipid and lipoprotein metabolism . Circulation . 1998;98:2088–2093
  8. Staels B , Koenig W , Habib A , et al.   Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators . Nature . 1998;393:790–793
  9. Marx N , Plutzky J . PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule 1 expression in human endothelial cells . Circulation . 1999;99:3125–3131
  10. Marx N , Plutzky J . PPARalpha activators inhibit tissue factor expression and activity in human monocytes . Circulation . 2001;103:213–219
  11. Tracy RP , Lemaitre RN , Psaty BM , et al.   Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project . Arterioscler Thromb Vasc Biol . 1997;17:1121–1127
  12. Ridker PM , Buring JE , Shih J , Matias M , Hennekens CH . Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women . Circulation . 1998;98:731–733
  13. Koenig W , Sund M , Frohlich M , et al.   C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men (results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992) . Circulation . 1999;99:237–242
  14. Strandberg TE , Tilvis RS . C-reactive protein, cardiovascular risk factors, and mortality in a prospective study in the elderly . Arterioscler Thromb Vasc Biol . 2000;20:1057–1060
  15. Whicher JT , Chambers RE , Higginson J , Nashef L , Higgins PG . Acute phase response of serum amyloid A protein and C reactive protein to the common cold and influenza . J Clin Pathol . 1985;38:312–316
  16. Nakayama T , Sonoda S , Urano T , Yamada T , Okada M . Monitoring both serum amyloid protein A and C-reactive protein as inflammatory markers in infectious diseases . Clin Chem . 1993;39:293–297

 Support was provided in part by the National Heart, Lung, and Blood Institute cooperative agreement grants U01 HL72524-01, HL72524-02, HL72524-03, and HL72524-04.

PII: S0022-2143(05)00125-3

doi: 10.1016/j.lab.2005.03.009

The Journal of Laboratory and Clinical Medicine
Volume 145, Issue 6 , Pages 323-327 , June 2005

Article Tools